**Information for publication**

1. **Materials & methods:**Please refer to the version number of the database used for your analysis
2. **Add below paragraph to the acknowledgements:**This work was supported by the Movember Foundation. The funder did not play any role in the study design, collection, analysis or interpretation of data, or in the drafting of this paper.
3. **One GAP3 MT PIs should be co-authors and as such provide input (any position is fine)**Monique Roobol (Erasmus Medical Center, Rotterdam, The Netherlands), m.roobol@erasmusmc.nl

Chris Bangma (Erasmus Medical Center, Rotterdam, The Netherlands), c.h.bangma@erasmusmc.nl

1. **The consortium should be added as last author of all GAP3 publications:**Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium a*a. The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium members presented in Appendix A.*

**Appendix A. Members of The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium**

Principle Investigators: Bruce Trock (Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, USA), Behfar Ehdaie (Memorial Sloan Kettering Cancer Center, New York, USA), Peter Carroll (University of California San Francisco, San Francisco, USA), Christopher Filson (Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA), Jeri Kim / Christopher Logothetis (MD Anderson Cancer Centre, Houston, USA), Todd Morgan (University of Michigan and Michigan Urological Surgery Improvement Collaborative (MUSIC), Michigan, USA), Laurence Klotz (University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada), Tom Pickles (University of British Columbia, BC Cancer Agency, Vancouver, Canada), Eric Hyndman (University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada), Caroline Moore (University College London & University College London Hospital Trust, London, UK), Vincent Gnanapragasam (University of Cambridge & Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK), Mieke Van Hemelrijck (King's College London, London, UK & Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Prokar Dasgupta (Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Chris Bangma (Erasmus Medical Center, Rotterdam, The Netherlands/ representative of Prostate cancer Research International Active Surveillance (PRIAS) consortium), Monique Roobol (Erasmus Medical Center, Rotterdam, The Netherlands/ representative of Prostate cancer Research International Active Surveillance (PRIAS) consortium), Arnauld Villers (Lille University Hospital Center, Lille, France), Antti Rannikko (Helsinki University and Helsinki University Hospital, Helsinki, Finland), Riccardo Valdagni (Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Radiation Oncology 1 and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Antoinette Perry (University College Dublin, Dublin, Ireland), Jonas Hugosson (Sahlgrenska University Hospital, Göteborg, Sweden), Jose Rubio-Briones (Instituto Valenciano de Oncología, Valencia, Spain), Anders Bjartell (Skåne University Hospital, Malmö, Sweden), Lukas Hefermehl (Kantonsspital Baden, Baden, Switzerland), Lee Lui Shiong (Singapore General Hospital, Singapore, Singapore), Mark Frydenberg (Monash Health; Monash University, Melbourne, Australia), Yoshiyuki Kakehi / Mikio Sugimoto (Kagawa University Faculty of Medicine, Kagawa, Japan), Byung Ha Chung (Gangnam Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea)

Pathologist: Theo van der Kwast (Princess Margaret Cancer Centre, Toronto, Canada).

Technology Research Partners: Henk Obbink (Royal Philips, Eindhoven, the Netherlands), Wim van der Linden (Royal Philips, Eindhoven, the Netherlands), Tim Hulsen (Royal Philips, Eindhoven, the Netherlands), Cees de Jonge (Royal Philips, Eindhoven, the Netherlands).

Advisory Regional statisticians: Mike Kattan (Cleveland Clinic, Cleveland, Ohio, USA), Ji Xinge (Cleveland Clinic, Cleveland, Ohio, USA), Kenneth Muir (University of Manchester, Manchester, UK), Artitaya Lophatananon (University of Manchester, Manchester, UK), Michael Fahey (Epworth HealthCare, Melbourne, Australia), Ewout Steyerberg (Erasmus Medical Center, Rotterdam, The Netherlands), Daan Nieboer (Erasmus Medical Center, Rotterdam, The Netherlands); Liying Zhang (University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada)

Executive Regional statisticians: Ewout Steyerberg (Erasmus Medical Center, Rotterdam, The Netherlands), Daan Nieboer (Erasmus Medical Center, Rotterdam, The Netherlands); Kerri Beckmann (King's College London, London, UK & Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Brian Denton (University of Michigan, Michigan, USA), Andrew Hayen (University of Technology Sydney, Australia), Paul Boutros (Ontario Institute of Cancer Research, Toronto, Ontario, Canada).

Clinical Research Partners’ IT Experts: Wei Guo (Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, USA), Nicole Benfante (Memorial Sloan Kettering Cancer Center, New York, USA), Janet Cowan (University of California San Francisco, San Francisco, USA), Dattatraya Patil (Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA), Emily Tolosa (MD Anderson Cancer Centre, Houston, Texas, USA), Tae-Kyung Kim (University of Michigan and Michigan Urological Surgery Improvement Collaborative, Ann Arbor, Michigan, USA), Alexandre Mamedov (University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada), Vincent LaPointe (University of British Columbia, BC Cancer Agency, Vancouver, Canada), Trafford Crump (University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada), Vasilis Stavrinides (University College London & University College London Hospital Trust, London, UK), Jenna Kimberly-Duffell (University of Cambridge & Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK), Aida Santaolalla (King's College London, London, UK & Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Daan Nieboer (Erasmus Medical Center, Rotterdam, The Netherlands), Jonathan Olivier (Lille University Hospital Center, Lille, France), Tiziana Rancati (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy), Helén Ahlgren (Sahlgrenska University Hospital, Göteborg, Sweden), Juanma Mascarós (Instituto Valenciano de Oncología, Valencia, Spain), Annica Löfgren (Skåne University Hospital, Malmö, Sweden), Kurt Lehmann (Kantonsspital Baden, Baden, Switzerland), Catherine Han Lin (Monash University and Epworth HealthCare, Melbourne, Australia), Hiromi Hirama (Kagawa University, Kagawa, Japan), Kwang Suk Lee (Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea).

Research Advisory Committee: Guido Jenster (Erasmus MC, Rotterdam, the Netherlands), Anssi Auvinen (University of Tampere, Tampere, Finland), Anders Bjartell (Skåne University Hospital, Malmö, Sweden), Masoom Haider (University of Toronto, Toronto, Canada), Kees van Bochove (The Hyve B.V. Utrecht, Utrecht, the Netherlands), Ballentine Carter (Johns Hopkins University, Baltimore, USA – until 2018).

Management team: Sam Gledhill (Movember Foundation, Melbourne, Australia), Mark Buzza / Michelle Kouspou (Movember Foundation, Melbourne, Australia), Chris Bangma (Erasmus Medical Center, Rotterdam, The Netherlands), Monique Roobol (Erasmus Medical Center, Rotterdam, The Netherlands), Sophie Bruinsma / Jozien Helleman (Erasmus Medical Center, Rotterdam, The Netherlands).